Copyright Reports & Markets. All rights reserved.

Global Neuroendocrine Tumor Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Neuroendocrine Tumor Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Product
      • 1.4.2 mTOR protein inhibitors
      • 1.4.3 Tyrosine kinase 3 inhibitors
      • 1.4.4 Somatostatin receptor antagonists
      • 1.4.5 Growth hormone releasing factor antagonists
      • 1.4.6 Somatostatin receptor agonists
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Neuroendocrine Tumor Drug Market Size
      • 2.1.1 Global Neuroendocrine Tumor Drug Revenue 2014-2025
      • 2.1.2 Global Neuroendocrine Tumor Drug Sales 2014-2025
    • 2.2 Neuroendocrine Tumor Drug Growth Rate by Regions
      • 2.2.1 Global Neuroendocrine Tumor Drug Sales by Regions
      • 2.2.2 Global Neuroendocrine Tumor Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Neuroendocrine Tumor Drug Sales by Manufacturers
      • 3.1.1 Neuroendocrine Tumor Drug Sales by Manufacturers
      • 3.1.2 Neuroendocrine Tumor Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Neuroendocrine Tumor Drug Revenue by Manufacturers
      • 3.2.1 Neuroendocrine Tumor Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Neuroendocrine Tumor Drug Price by Manufacturers
    • 3.4 Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Neuroendocrine Tumor Drug Sales by Product
    • 4.2 Global Neuroendocrine Tumor Drug Revenue by Product
    • 4.3 Neuroendocrine Tumor Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Neuroendocrine Tumor Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Neuroendocrine Tumor Drug by Countries
      • 6.1.1 North America Neuroendocrine Tumor Drug Sales by Countries
      • 6.1.2 North America Neuroendocrine Tumor Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Neuroendocrine Tumor Drug by Product
    • 6.3 North America Neuroendocrine Tumor Drug by End User

    7 Europe

    • 7.1 Europe Neuroendocrine Tumor Drug by Countries
      • 7.1.1 Europe Neuroendocrine Tumor Drug Sales by Countries
      • 7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Neuroendocrine Tumor Drug by Product
    • 7.3 Europe Neuroendocrine Tumor Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Neuroendocrine Tumor Drug by Countries
      • 8.1.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Countries
      • 8.1.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Neuroendocrine Tumor Drug by Product
    • 8.3 Asia Pacific Neuroendocrine Tumor Drug by End User

    9 Central & South America

    • 9.1 Central & South America Neuroendocrine Tumor Drug by Countries
      • 9.1.1 Central & South America Neuroendocrine Tumor Drug Sales by Countries
      • 9.1.2 Central & South America Neuroendocrine Tumor Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Neuroendocrine Tumor Drug by Product
    • 9.3 Central & South America Neuroendocrine Tumor Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Neuroendocrine Tumor Drug by Countries
      • 10.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Countries
      • 10.1.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Neuroendocrine Tumor Drug by Product
    • 10.3 Middle East and Africa Neuroendocrine Tumor Drug by End User

    11 Company Profiles

    • 11.1 Eisai
      • 11.1.1 Eisai Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
      • 11.1.5 Eisai Recent Development
    • 11.2 Exelixis, Inc.
      • 11.2.1 Exelixis, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
      • 11.2.5 Exelixis, Inc. Recent Development
    • 11.3 Foresee Pharmaceuticals, LLC
      • 11.3.1 Foresee Pharmaceuticals, LLC Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
      • 11.3.5 Foresee Pharmaceuticals, LLC Recent Development
    • 11.4 Hutchison MediPharma Limited
      • 11.4.1 Hutchison MediPharma Limited Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
      • 11.4.5 Hutchison MediPharma Limited Recent Development
    • 11.5 Intezyne, Inc
      • 11.5.1 Intezyne, Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
      • 11.5.5 Intezyne, Inc Recent Development
    • 11.6 INVENT Pharmaceuticals, Inc.
      • 11.6.1 INVENT Pharmaceuticals, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
      • 11.6.5 INVENT Pharmaceuticals, Inc. Recent Development
    • 11.7 Ipsen S.A.
      • 11.7.1 Ipsen S.A. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
      • 11.7.5 Ipsen S.A. Recent Development
    • 11.8 Jiangsu Hengrui Medicine Co., Ltd.
      • 11.8.1 Jiangsu Hengrui Medicine Co., Ltd. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
      • 11.8.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
    • 11.9 Karyopharm Therapeutics, Inc.
      • 11.9.1 Karyopharm Therapeutics, Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
      • 11.9.5 Karyopharm Therapeutics, Inc. Recent Development
    • 11.10 Lexicon Pharmaceuticals, Inc.
      • 11.10.1 Lexicon Pharmaceuticals, Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
      • 11.10.5 Lexicon Pharmaceuticals, Inc. Recent Development
    • 11.11 Midatech Pharma Plc .
    • 11.12 Millennium Pharmaceuticals, Inc.
    • 11.13 MolMed S.p.A.
    • 11.14 Northwest Biotherapeutics, Inc.
    • 11.15 Novartis AG
    • 11.16 OctreoPharm Sciences GmbH
    • 11.17 OXiGENE, Inc.

    12 Future Forecast

    • 12.1 Neuroendocrine Tumor Drug Market Forecast by Regions
      • 12.1.1 Global Neuroendocrine Tumor Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Neuroendocrine Tumor Drug Market Forecast by Product
      • 12.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Product 2019-2025
    • 12.3 Neuroendocrine Tumor Drug Market Forecast by End User
    • 12.4 North America Neuroendocrine Tumor Drug Forecast
    • 12.5 Europe Neuroendocrine Tumor Drug Forecast
    • 12.6 Asia Pacific Neuroendocrine Tumor Drug Forecast
    • 12.7 Central & South America Neuroendocrine Tumor Drug Forecast
    • 12.8 Middle East and Africa Neuroendocrine Tumor Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Neuroendocrine Tumor Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Neuroendocrine Tumor Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neuroendocrine Tumor Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Neuroendocrine Tumor Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neuroendocrine Tumor Drug in these regions.
      This research report categorizes the global Neuroendocrine Tumor Drug market by top players/brands, region, type and end user. This report also studies the global Neuroendocrine Tumor Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Eisai
      Exelixis, Inc.
      Foresee Pharmaceuticals, LLC
      Hutchison MediPharma Limited
      Intezyne, Inc
      INVENT Pharmaceuticals, Inc.
      Ipsen S.A.
      Jiangsu Hengrui Medicine Co., Ltd.
      Karyopharm Therapeutics, Inc.
      Lexicon Pharmaceuticals, Inc.
      Midatech Pharma Plc .
      Millennium Pharmaceuticals, Inc.
      MolMed S.p.A.
      Northwest Biotherapeutics, Inc.
      Novartis AG
      OctreoPharm Sciences GmbH
      OXiGENE, Inc.

      Market size by Product
      mTOR protein inhibitors
      Tyrosine kinase 3 inhibitors
      Somatostatin receptor antagonists
      Growth hormone releasing factor antagonists
      Somatostatin receptor agonists
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Neuroendocrine Tumor Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Neuroendocrine Tumor Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Neuroendocrine Tumor Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Neuroendocrine Tumor Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Neuroendocrine Tumor Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroendocrine Tumor Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now